PMID- 26364730
OWN - NLM
STAT- MEDLINE
DCOM- 20160923
LR  - 20170801
IS  - 1573-2509 (Electronic)
IS  - 0920-9964 (Linking)
VI  - 169
IP  - 1-3
DP  - 2015 Dec
TI  - Antipsychotic treatment reduces psychotic symptoms and markers of low-grade 
      inflammation in first episode psychosis patients, but increases their body mass 
      index.
PG  - 22-29
LID - S0920-9964(15)00456-9 [pii]
LID - 10.1016/j.schres.2015.08.027 [doi]
AB  - OBJECTIVE: The main goal of the present study was to analyze levels of cytokines 
      of the interleukin family (IL-1alpha, IL-1beta, IL-2, IL-4, IL-6, IL-8 and IL-10), 
      interferon-gamma (IFN-gamma), monocyte chemoattractant protein-1 (MCP1), tumor 
      necrosis factor-alpha (TNF-alpha), and vascular endothelial and endothelial growth 
      factors (VEGF and EGF), in the blood samples of first-episode psychosis (FEP) 
      patients before and seven months after the start of antipsychotic medication use. 
      METHOD: 38 anti-psychotic medication-naive FEP patients and 37 healthy controls 
      (HC) were recruited. Biochip array technology was used to measure cytokines and 
      growth factors. RESULTS: The comparison of these markers in FEP patients and HC 
      revealed significantly higher levels of EGF, IL-4 and IL-6 and significantly 
      lower level of IL-1beta in FEP patients before the antipsychotic treatment. Multiple 
      regression analysis demonstrated significant correlations between FEP and EGF, 
      IL-1beta and smoking. Treatment with antipsychotic drugs resulted in a statistically 
      significant amelioration of the symptoms of psychosis, but caused a significant 
      increase in the body mass index (BMI) of patients. Levels of EGF, IL-2, VEGF, 
      IL-6, IFN-gamma, IL-4, IL-8 and IL-1alpha were significantly lower in treated FEP 
      patients compared to premedication levels. CONCLUSIONS: According to the present 
      study, EGF and IL-1beta are markers of FEP. Antipsychotic drug treatment resulted in 
      a significant clinical improvement of FEP patients and the suppression of 
      positive symptoms was correlated with the decreased levels of EGF, IL-2 and IL-4. 
      EGF was the strongest marker of FEP and treatment efficiency among the measured 
      cytokines and growth factors.
CI  - Copyright (c) 2015 Elsevier B.V. All rights reserved.
FAU - Haring, Liina
AU  - Haring L
AD  - Psychiatry Clinic of Tartu University Hospital, 31 Raja Street, Tartu 50417, 
      Estonia. Electronic address: Liina.Haring@kliinikum.ee.
FAU - Koido, Kati
AU  - Koido K
AD  - Institute of Biomedicine and Translational Medicine, University of Tartu, 19 
      Ravila Street, Tartu 50411, Estonia; Centre of Excellence for Translational 
      Medicine, University of Tartu, 19 Ravila Street, Tartu 50411, Estonia. Electronic 
      address: Kati.Koido@ut.ee.
FAU - Vasar, Veiko
AU  - Vasar V
AD  - Psychiatry Clinic of Tartu University Hospital, 31 Raja Street, Tartu 50417, 
      Estonia. Electronic address: Veiko.Vasar@kliinikum.ee.
FAU - Leping, Vambola
AU  - Leping V
AD  - Institute of Computer Science, University of Tartu, 2 Liivi Street, Tartu 50409, 
      Estonia. Electronic address: Vambola.Leping@ut.ee.
FAU - Zilmer, Kersti
AU  - Zilmer K
AD  - Institute of Biomedicine and Translational Medicine, University of Tartu, 19 
      Ravila Street, Tartu 50411, Estonia; Centre of Excellence for Translational 
      Medicine, University of Tartu, 19 Ravila Street, Tartu 50411, Estonia. Electronic 
      address: Kersti.Zilmer@ut.ee.
FAU - Zilmer, Mihkel
AU  - Zilmer M
AD  - Institute of Biomedicine and Translational Medicine, University of Tartu, 19 
      Ravila Street, Tartu 50411, Estonia; Centre of Excellence for Translational 
      Medicine, University of Tartu, 19 Ravila Street, Tartu 50411, Estonia. Electronic 
      address: Mihkel.Zilmer@ut.ee.
FAU - Vasar, Eero
AU  - Vasar E
AD  - Institute of Biomedicine and Translational Medicine, University of Tartu, 19 
      Ravila Street, Tartu 50411, Estonia; Centre of Excellence for Translational 
      Medicine, University of Tartu, 19 Ravila Street, Tartu 50411, Estonia. Electronic 
      address: Eero.Vasar@ut.ee.
LA  - eng
PT  - Journal Article
DEP - 20150911
PL  - Netherlands
TA  - Schizophr Res
JT  - Schizophrenia research
JID - 8804207
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Cytokines)
SB  - IM
MH  - Acute Disease
MH  - Adolescent
MH  - Adult
MH  - Antipsychotic Agents/*adverse effects/*therapeutic use
MH  - Biomarkers/blood
MH  - Blood Chemical Analysis
MH  - *Body Mass Index
MH  - Cytokines/*blood
MH  - Female
MH  - Humans
MH  - Male
MH  - Protein Array Analysis
MH  - Psychiatric Status Rating Scales
MH  - Psychotic Disorders/complications/*drug therapy/*physiopathology
MH  - Regression Analysis
MH  - Smoking/physiopathology
MH  - Tobacco Use Disorder/complications/physiopathology
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - Antipsychotic treatment
OT  - Cytokines
OT  - First-episode psychosis
OT  - Growth factors
OT  - Inflammation
EDAT- 2015/09/15 06:00
MHDA- 2016/09/24 06:00
CRDT- 2015/09/15 06:00
PHST- 2015/02/26 00:00 [received]
PHST- 2015/08/19 00:00 [revised]
PHST- 2015/08/20 00:00 [accepted]
PHST- 2015/09/15 06:00 [entrez]
PHST- 2015/09/15 06:00 [pubmed]
PHST- 2016/09/24 06:00 [medline]
AID - S0920-9964(15)00456-9 [pii]
AID - 10.1016/j.schres.2015.08.027 [doi]
PST - ppublish
SO  - Schizophr Res. 2015 Dec;169(1-3):22-29. doi: 10.1016/j.schres.2015.08.027. Epub 
      2015 Sep 11.